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Abstract
Purpose of review—Recent clinical trials and animal studies indicate that resistant starches
(RS) may be beneficial therapeutic tools for the management of metabolic diseases. The purpose
of this review is to summarize these findings and discuss the established and proposed
mechanisms by which RS exert their benefits. We also examine open questions regarding how RS
improve metabolism and propose future research directions for the field.
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Recent findings—Data from both humans and animal models clearly support a role for RS in
improving a variety of metabolic features; however, discrepancies do exist regarding specific
effects. Concomitant improvements in both insulin levels and body fat depots are often reported in
rodents fed RS whereas RS feeding in humans improves insulin sensitivity without having a major
impact on fat mass. These differences could be explained by the coexistence of several
mechanisms (both gut microbiota-dependent and gut microbiota-independent) underpinning the
metabolic benefits of RS.
Summary—Together, the studies presented in this review offer new insights into the potential
pathways by which RS enhance metabolic health, including modulation of the gut microbiota, gut
peptides, circulating inflammatory mediators, innate immune cells, and the bile acid cycle.
Keywords
Resistant starches; insulin sensitivity; gut microbiota; bile acids; macrophages
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Obesity is rapidly becoming a major global health challenge. From 1980 to 2013, the
proportion of overweight adults increased worldwide from 29% to 37% [1]. Abdominal
adiposity is the primary risk factor for development of metabolic diseases such as type 2
diabetes (T2D) and cardiovascular disease [2;3].
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Traditional approaches to treating obesity and its related diseases have emphasized
appropriate dietary choices and increased physical activity. One of the nutritional
interventions proposed to counteract metabolic diseases is dietary supplementation with
resistant starches (RS). RS include all starch and starch degradation products that escape
digestion in the small intestine of healthy individuals because they are physically
inaccessible, either within the food matrix (RS1) or within starch granules (RS2) or because
they are present as retrograded starch (RS3), which is produced during food manufacture
and preparation. In addition, starch can also be chemically modified (RS4) to make it
resistant to enzymatic digestion [4*].
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RS offer many practical advantages for use in the management of obesity-associated
pathologies when compared to other fibers. RS can easily replace regular starch in baked
goods and, by being non-digestible, can reduce both the caloric density and glycemic index
of food products. However, RS exert physiological effects that go beyond resistance to
digestibility, including modulation of satiety perception, dyslipidemia, insulin sensitivity,
and glycemic control in both healthy and obese volunteers as well as in patients with
metabolic syndrome [5*;6*;7**].
In this review, we provide an overview of recent studies that investigated the potential of
various RS types to manage metabolic disorders. We then discuss the established and
proposed mechanisms by which RS exert metabolic benefits. Finally, we examine open
questions regarding how RS improve metabolism and propose future research directions for
the field.

Resistant starches to combat metabolic diseases
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RS were first characterized in 1982 and then rapidly studied for their ability to improve
colonic health [8]. Since then, considerable effort has also been devoted to investigating the
metabolic effects of RS using both human clinical trials and animal models [5*;6*]. In
particular, several recent studies have strengthened the concept that RS confer metabolic
benefits.
Modulation of insulin resistance and glucose homeostasis
Improved insulin resistance and glucose homeostasis are arguably the best-characterized
metabolic benefits associated with RS consumption [6;9]. Although these effects are well
documented in healthy individuals and those with metabolic syndrome, information
regarding its impact on populations with established metabolic disease is lacking.
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In a recent clinical trial, Bodinham and colleagues addressed this issue by assessing the
effects of RS2 consumption on insulin sensitivity and glucose control in patients with T2D
[6]**]. RS2 improved postprandial glucose levels, but had no impact on hepatic or
peripheral insulin sensitivity as assessed by the hyperinsulinemic clamp technique [6]**]. It
appears that RS can improve insulin sensitivity in healthy and pre-diabetic individuals but
not after T2D has been established.
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Recent studies regarding RS feeding and glucose control unfortunately show conflicting
results. In particular, Zhou et al. observed significant decreases in blood glucose levels
compared to controls when RS2 (8% w/w) was fed to streptozotocin-induced diabetic rats
[10]. This was in contrast to Harazaki et al. who reported that feeding RS2 (55% w/w)
significantly decreased fasting insulin levels and the index of insulin resistance but did not
change glucose tolerance in an OLETF rat model of T2D [11*].
There is clearly good evidence that RS improve glucose metabolism beyond what would be
expected from its reduced glycemic index, but to what extent established pathologies can be
reversed is still unclear, and some studies do not show a beneficial effect on glycemic
variables [12;13*]. Differences in RS intake levels, RS source, timeframe and disease status,
among other factors (such as gut microbiota variation), could explain these apparent
discrepancies, as discussed later in this review.
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Alterations in body weight, body composition, and dyslipidemia
In 2014, Higgins provided a comprehensive review concerning the impact of RS on energy
balance, body weight, and body composition [14**]. Since then, Nichenametla and
colleagues published a human crossover, dietary intervention comparing effects of RS4enriched flour with regular flour in healthy individuals and subjects with metabolic
syndrome. Patients with metabolic syndrome experienced significant improvements in their
blood cholesterol profiles [13*]. Similarly, Dodevska et al. showed that increasing RS intake
during a lifestyle intervention for prediabetic overweight and obese adults significantly
decreased their total serum cholesterol levels [12]. These two clinical trials provide exciting
evidence that RS feeding positively influences dyslipidemia.
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Also of interest, Nichenametla et al. found that only healthy persons consuming RS4enriched flour experienced significant (albeit it minor) effects on their waist circumference
and percent body fat; no such effects were observed for individuals with metabolic
syndrome [13*]. This is in line with the aforementioned Bodinham et al. study where T2D
patients experienced no changes in body weight, fat mass, or body fat depots despite
decreases in fasting free fatty acid levels [6]. Dodevska and colleagues did report significant
decreases in body weight and waist circumference, but the changes were minor [12]. All
told, these recent reports demonstrate that dietary supplementation with RS has little to no
impact on body composition in humans with metabolic disease.

Mechanisms underpinning the health effects of RS
Author Manuscript

The ways in which RS exert their health effects are insufficiently understood, but recent
research has provided new insight into potential mechanisms. It has long been recognized
that RS essentially function like fermentable fibers as well as bulking agents. To that end,
we will examine the potential mechanisms by which RS impact metabolic processes,
including those that involve the gut microbiota and those that may not.
The gut microbiota, short-chain fatty acids, and beyond
The community of microbes inhabiting the intestinal tract (the gut microbiota) provides
critical control over host energy metabolism, insulin sensitivity, and immune development
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and regulation [15**–17]. RS remain intact until reaching the distal small and large
intestines—here, they can be fermented by the microbiota, ultimately modulating both
microbial composition and activity [18–23]. Consequently, the gut microbiota has been
proposed as a key component in mediating the metabolic benefits of RS [5*;14**].
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Microbial metabolites that result from RS fermentation, especially short chain fatty acids
(SCFAs), have several physiological, metabolic, and immunological effects that could bring
about the health benefits of RS. SCFA can trigger the release of gut peptides involved in
appetite regulation and glucose homeostasis, such as peptide YY (PYY) and glucagon-like
peptide 1 (GLP-1) [24–26] (Figure 1). In accordance with this hypothesis, Zhou and
colleagues showed that feeding RS2 to mice (30% w/w) increased both the full cecum and
cecal tissue weights (indicative of fermentation), increased cecal expression of PYY and
proglucagon (the precursor of GLP-1), and decreased body fat. The anti-obesity effect was
dependent on GLP-1R and PYY, as the RS-mediated reduction in body fat was not observed
in mice receiving a daily injection of a PYY receptor antagonist or in GLP-1-receptor
deficient mice [29**]. Although this study did not address glucose homeostasis, future
research should determine if GLP-1 induction is a mechanism by which RS improves
glucose control.
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Information regarding the impact of RS2 on GLP-1 in human trials is inconsistent. RSmediated improvements in insulin sensitivity have been observed without a concomitant
impact on GLP-1 levels [5]. In the Bodinham et al. study, feeding RS2 to T2D patients for
12 weeks lowered fasting GLP-1 levels but increased GLP-1 postprandial excursion during a
meal tolerance test [6]. The latter result is in contrast with the previous observation that
postprandial GLP-1 levels were significantly lower following acute RS2 consumption [30].
Bodinham et al. also reported significant decreases in butyrate and propionate (with no
change in acetate) levels in the serum of RS2-fed T2D patients. Although a decreased serum
level of these SCFA does not necessarily preclude their production in the intestine, it does,
however, exclude these microbial metabolites as systemic drivers of any peripheral effects
of RS2 such as lipolysis.
Modulation of bile acids, innate immunity, and inflammatory mediators
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By functioning like a fiber, and subsequently bulking and increasing digesta viscosity, RS
are also likely to exert some effects independently of their impact on the gut microbiota.
One of these alternative mechanisms could involve bile acids. Indeed, various types of RS
have been shown to impact bile acid excretion [31]. Bile acids control glucose homeostasis
and insulin resistance via binding of the nuclear farnesoid X receptor (FXR) and the cell
membrane receptor TGR5 [27]. Indeed, recent work has elegantly shown that macrophagespecific deletion of Tgr5 increased adipose tissue macrophage accumulation and aggravated
insulin resistance in obese animals [28]. How RS modulate bile acid profiles remains to be
more deeply characterized, but two scenarios can be envisioned. On one hand, RS could
influence the bile pool by modulating specific microbial taxa that chemically transform bile
acids. On the other, RS may impact the concentration and reabsorption of bile acids via
direct binding, bulking, and increasing viscosity [31] (Figure 1).

Curr Opin Clin Nutr Metab Care. Author manuscript; available in PMC 2016 November 01.

Bindels et al.

Page 5

Author Manuscript
Author Manuscript

The notion that RS modulates the immune system and insulin resistance through modulation
of the bile acid profile is an underexplored concept that deserves further attention. The
aforementioned work by Harazaki et al. describing reduced insulinemia in RS2-fed T2D rats
was the first to report a potential link between RS and regulation of immune cell
populations. Specifically, feeding RS was associated with decreased adipose tissue
expression of CD11c, a marker expressed on antigen presenting cells and pro-inflammatory
macrophages [11*]. This finding is of considerable interest, as deletion of CD11c expressing
cells has previously been shown to normalize insulin sensitivity in obese, insulin-resistant
animals [32]. Macrophages can also secrete a myriad of pro-inflammatory cytokines,
including TNF-Kα, IL-6 and IL-β. Bodinham et al. reported a 60% decrease in plasma TNFα levels following 12 weeks of RS2 feeding. Over expression of TNF-α has long been
hypothesized to play a significant role in the pathophysiology of insulin resistance [33].
Regulation of innate immune cells and their inflammatory mediators via bile acids may be a
potential mechanism by which RS improves glucose homeostasis and insulin resistance, but
additional studies are needed.

Open questions and future research directions
Several challenges remain in regards to understanding how RS improve metabolism. Here,
we identify a few key questions for the field and discuss potential answers in light of the
latest findings.
What is the exact role of the gut microbiota in the health effects of RS?
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Recent evidence implicates the gut microbiota in precipitating the numerous health effects
attributed to RS. Like other fibers, RS are fermented by the gut microbiota to SCFA—
microbial metabolites whose physiological effects are increasingly recognized [24;25*]. In
addition, RS shift the intestinal microbiota composition by enhancing putatively healthpromoting taxa. Human trials in healthy volunteers demonstrated that feeding RS2 and RS3
increased the abundance of Ruminococcus bromii and Eubacterium rectale, while RS4 had a
major bifidogenic effect [18;34]. In addition, administration of RS3 to pigs increased
Faecalibacterium prausnitzii and reduced the abundance of Escherichia coli and
Pseudomonas spp. [21]. Eubacterium rectale and Faecalibacterium prausnitzii are major
butyrate producers with anti-inflammatory properties [35], and bifidobacteria are generally
considered health-promoting organisms, thus RS-induced shifts in microbiota composition,
in addition to metabolic effects, might contribute to health outcomes.
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Despite these promising findings, the exact role of the gut microbiota in mediating the
effects of RS has not been systematically studied. As we discussed above, several of the
beneficial effects of RS may occur without microbial contributions. Strong correlations
between RS feeding and taxa changes could result simply from host and microbiome
responding independently to the diet. Comparing the effects of RS in conventional and
germ-free animals would constitute a tractable model to separate direct versus microbiotamediated effects [36]. Recent work from our own laboratory has revealed that feeding RS2
or RS4 supplemented Western diets to both germ-free and conventionalized mice improved
their index of insulin resistance, indicating microbiome-independent mechanisms do exist
(LB Bindels, J Walter, and AE Ramer-Tait, unpublished data). As gnotobiotic mouse
Curr Opin Clin Nutr Metab Care. Author manuscript; available in PMC 2016 November 01.
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models and protocols for microbiota transplants become more widely available, this line of
research not only has the potential to determine the causative role of the microbiome in the
health effects of dietary fiber (which will be critical for determining which fibers qualify for
a prebiotic designation [37*]), but it will also facilitate direct testing of cultured strains with
specific characteristics to ultimately identify individual bacterial contributors and underlying
mechanisms [36].
What accounts for the discrepancies between animal and human studies?
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Concomitant improvements in both insulin levels and body fat depots are often reported in
rodents fed RS. This is in contrast to studies in healthy humans or patients with metabolic
syndrome where RS feeding improves insulin sensitivity without having a major impact on
fat mass. Several factors likely contribute to this discrepancy, one of which is the gut
microbiota. Human and rodent microbiomes are strikingly dissimilar and may vary widely in
their response to RS. Another explanation could be the vastly different RS doses fed during
the animal studies, which often range from 30% to 55% of the diet. Unfortunately, these
doses are likely not realistic for human diets. Feeding higher doses of RS during animal
studies may also explain why increased SCFA production is frequently reported in rodents
but not humans, as SCFA production is a dose-dependent phenomenon. SCFA, working to
stimulate PYY and GLP-1 secretion, could potentially reduce fat mass whereas other
mechanisms (independent of SCFA and GLP-1) may improve insulin sensitivity. This
working model would explain why RS feeding does not have a profound impact on fat mass
in humans but still enhances insulin sensitivity.
What accounts for the variation and inconsistency among experiments?
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Beyond the discrepancies described among the various animal models and human
populations, inconsistencies have even been reported within the same experimental design.
What causes this variation is not understood. However, interactions between RS and the gut
microbiome could potentially contribute, as microbiota composition differs widely among
animal facilities, is highly individualized in humans (especially in westernized societies)
[38], and is influenced by dietary regimen. If RS do indeed impact host physiology via
effects on the microbiome, one would assume these responses to differ among vivaria or
people. The ability of RS2 to reduce fat mass in mice has not been detected consistently
across experiments and is associated with whether or not a particular cohort of mice
fermented the RS [5]. These observations collectively point to functional differences in the
microbiome. In addition, human microbiomes also vary in their ability to utilize RS. For
example, Ruminoccocus bromii has been shown to be a keystone bacterial species required
to begin the RS3 degradation process, and the starch remains untouched in persons who do
not harbor this species [39]. There have been attempts to determine microbiome
responsiveness to RS3 based on characteristics of an individual’s fecal microbiome
composition, especially at baseline [22*]. This concept is still in its infancy, but if the
microbiota indeed confers the metabolic effects of RS, variation in the functional response
of individuals’ gut microbes will likely impact the outcomes of clinical trials. Considering
these characteristics will introduce the microbiome into the realm of personalized nutrition.
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What is the functional relevance of the chemical differences among RS types?
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We often speak of RS as a whole. However, RS encompass a wide variety of structures, and
this heterogeneity could also explain, at least in part, some apparent discrepancies among
studies. Several pathways are likely involved in mediating the metabolic benefits associated
with consuming RS. It is therefore quite possible that the relative contribution of each of
these pathways will vary from one structure to another. Due to their inherent and distinct
physicochemical properties, specific types of RS or even specific structures within a type
may favor the growth of different gut microorganisms, which relates to disparities in how
various RS shape the human microbiome [4;18;34;40]. Thus, systematic comparisons of
different types of RS regarding their unique ability to improve metabolic alterations are
warranted.
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Conclusions
The metabolic benefits of RS for humans have been well-established using gold standard
techniques such as the euglycemic-hyperinsulinemic clamp. However, the mechanisms
underpinning these effects remain to be elucidated. Progress in obtaining such an
understanding requires a combination of clinical trials and experiments in animal models.
Specifically, mechanisms must first be investigated using animal models—this information
should then inform and be corroborated by clinical trials in which key biomarkers are
assessed. In this framework, collecting samples from patients consuming RS to investigate
gut microbiota composition and function, bile acid profiles, and SCFA production becomes
essential. Such research will ultimately provide the mechanistic insight needed to better
design dietary strategies for specific human populations that, when combined with
microbiome assessment, exemplify the concept of personalized nutrition.
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Key points
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•

Recent clinical studies show that feeding resistant starches can have a positive
effect on insulin sensitivity and dyslipidemia, with little to no impact on body
composition.

•

Several pathways – gut microbiota-dependent and gut microbiota-independent –
are likely involved in conferring the metabolic benefits associated with
consuming resistant starches.

•

Despite promising findings, the exact role of the gut microbiota in mediating the
metabolic benefits of resistant starches remains to be determined.

•

Gut microbiota variation among animal facilities, human populations, and even
individuals, might contribute to inconsistencies observed regarding the effects of
resistant starches.

•

Resistant starches encompass a wide variety of structures—this heterogeneity
must be considered and could explain, at least in part, some apparent
discrepancies among studies.
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Figure 1. Mechanistic insights into the metabolic benefits of RS

This figure summarizes various hypotheses regarding the mechanisms underlying the
beneficial effects conferred by RS consumption. RS could stimulate the microbial
production of SCFA, thereby increasing the production of PYY and GLP-1 by intestinal L
cells [24]. RS could also alter the bile acid profile via gut microbiota-dependent and
independent pathways. Bile acids control glucose homeostasis via binding of the nuclear
farnesoid X receptor (FXR) and the cell membrane receptor TGR5 [27]. In particular, recent
work has shown that macrophage-specific deletion of Tgr5 increased adipose tissue
macrophage accumulation and aggravated insulin resistance in obese animals [28]. GLP-1:
glucagon-like peptide 1; PYY: peptide YY, SCFA: short chain fatty acids.
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